VistaGen Therapeutics Inc.

0.1355-0.0005-0.37%Vol 2.97M1Y Perf -92.41%
Dec 2nd, 2022 16:00 DELAYED
BID0.1323 ASK0.1380
Open0.1400 Previous Close0.1360
Pre-Market- After-Market0.14
 - -  0.00 -0.22%
Target Price
6.50 
Analyst Rating
Hold 3.00
Potential %
4.70K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★★+     59.64
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.89 
Earnings Rating
Buy
Market Cap28.03M 
Earnings Date
10th Nov 2022
Alpha0.02 Standard Deviation0.31
Beta1.06 

Today's Price Range

0.13120.1401

52W Range

0.07682.11

5 Year PE Ratio Range

-2.20-1.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
11.61%
1 Month
4.80%
3 Months
-22.70%
6 Months
-88.22%
1 Year
-92.41%
3 Years
-67.74%
5 Years
-83.27%
10 Years
-

TickerPriceChg.Chg.%
VTGN0.1355-0.0005-0.37
AAPL147.81-0.5000-0.34
GOOG100.83-0.4500-0.44
MSFT255.020.33000.13
XOM109.86-0.9400-0.85
WFC45.94-0.9300-1.98
JNJ178.880.14000.08
FB196.640.99000.51
GE86.881.62001.90
JPM135.16-1.0800-0.79
Financial StrengthValueIndustryS&P 500US Markets
5.90
6.10
0.07
0.12
-4 604.50
Leverage Ratio 1.20
 
ProfitabilityValueIndustryS&P 500US Markets
-
34.71K
34.33K
-
-
RevenueValueIndustryS&P 500US Markets
-185 600.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.08-0.080.00
Q01 2023-0.09-0.10-11.11
Q04 2022-0.06-0.08-33.33
Q03 2022-0.08-0.0537.50
Q02 2022-0.05-0.07-40.00
Q01 2022-0.05-0.0420.00
Q04 2021-0.05-0.20-300.00
Q03 2021-0.05-0.07-40.00
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.060.00-
3/2023 QR-0.050.00-
3/2023 FY-0.283.45Positive
3/2024 FY-0.195.00Positive
Next Report Date-
Estimated EPS Next Report-0.07
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume2.97M
Shares Outstanding206.84K
Shares Float206.42M
Trades Count3.31K
Dollar Volume400.63K
Avg. Volume4.47M
Avg. Weekly Volume4.57M
Avg. Monthly Volume3.10M
Avg. Quarterly Volume5.73M

VistaGen Therapeutics Inc. (NASDAQ: VTGN) stock closed at 0.1355 per share at the end of the most recent trading day (a -0.37% change compared to the prior day closing price) with a volume of 2.97M shares and market capitalization of 28.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. VistaGen Therapeutics Inc. CEO is Shawn K. Singh.

The one-year performance of VistaGen Therapeutics Inc. stock is -92.41%, while year-to-date (YTD) performance is -93.05%. VTGN stock has a five-year performance of -83.27%. Its 52-week range is between 0.0768 and 2.11, which gives VTGN stock a 52-week price range ratio of 2.89%

VistaGen Therapeutics Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.86, a price-to-sale (PS) ratio of -136.52, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -91.63%, a ROC of -110.25% and a ROE of -117.34%. The company’s profit margin is -%, its EBITDA margin is 34 330.70%, and its revenue ttm is $-185 600.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from VistaGen Therapeutics Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.07 for the next earnings report. VistaGen Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for VistaGen Therapeutics Inc. is Hold (3), with a target price of $6.5, which is +4 697.05% compared to the current price. The earnings rating for VistaGen Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

VistaGen Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

VistaGen Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.43, ATR14 : 0.02, CCI20 : -10.07, Chaikin Money Flow : -0.08, MACD : 0.00, Money Flow Index : 57.83, ROC : -14.83, RSI : 46.94, STOCH (14,3) : 32.22, STOCH RSI : 0.86, UO : 37.68, Williams %R : -67.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of VistaGen Therapeutics Inc. in the last 12-months were: Jerrold D. Dotson (Option Excercise at a value of $18 750), Jerry B. Gin (Buy at a value of $17 870), Reid G. Adler (Buy at a value of $50 910), Shawn K. Singh (Buy at a value of $103 200), Shawn K. Singh (Option Excercise at a value of $100 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

VistaGen Therapeutics Inc.

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

CEO: Shawn K. Singh

Telephone: +1 650 577-3600

Address: 343 Allerton Avenue, San Francisco 94080, CA, US

Number of employees: 11

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

62%38%

Bearish Bullish

52%48%


News

Stocktwits